Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain

McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X, Barucki, H., Blewett, Sally Ann, Carangio, Antonella, Erichsen, Jonathan Thor ORCID: https://orcid.org/0000-0003-1545-9853, Andrei, G., Snoeck, R., De Clercq, E. and Balzarini, J. 2000. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. Journal of Medicinal Chemistry 43 (26) , pp. 4993-4997. 10.1021/jm000210m

Full text not available from this repository.

Abstract

In addition to our recent report on the potent anti-varicella-zoster virus (VZV) activity of some unusual bicyclic furopyrimidine nucleosides bearing long alkyl side chains, we herein report the further significant enhancement of the antiviral potency by inclusion of a phenyl group in the side chain of these compounds. The target structures were prepared by the Pd-catalyzed coupling of a series of para-substituted arylacetylenes with 5-iodo-2‘-deoxyuridine, to give intermediate 5-alkynyl nucleosides which were cyclized in the presence of Cu to give the desired bicyclic systems. The compounds display extraordinary potency and selectivity for VZV; the most active are ca. 10 000 times more potent than the reference compound acyclovir and ca. 100 times more potent than the alkyl analogues earlier reported by us. The current compounds show little cytotoxicity, leading to selectivity index values 1 000 000. From a range of DNA and RNA viruses tested, only VZV was inhibited by these compounds indicating their extreme selectivity for this target virus. The novelty of the molecules, coupled with their extreme potency and selectivity, their desirable physicochemical properties, and their relative ease of synthesis, makes them of considerable interest for potential drug development for VZV infections.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy Optometry and Vision Sciences Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Publisher:	ACS
ISSN:	0022-2623
Last Modified:	18 Oct 2022 14:32
URI:	https://orca.cardiff.ac.uk/id/eprint/17921

Citation Data

Cited 172 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item